- Home
- GRAL vs PHAR Comparison
GRAL vs PHAR Comparison
Compare GRAL & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GRAL
- PHAR
- Stock Information
- Founded
- GRAL 2016
- PHAR 1988
- Country
- GRAL United States
- PHAR Netherlands
- Employees
- GRAL N/A
- PHAR N/A
- Industry
- GRAL
- PHAR Biotechnology: Pharmaceutical Preparations
- Sector
- GRAL
- PHAR Health Care
- Exchange
- GRAL NYSE
- PHAR Nasdaq
- Market Cap
- GRAL 610.9M
- PHAR 627.5M
- IPO Year
- GRAL N/A
- PHAR N/A
- Fundamental
- Price
- GRAL $16.96
- PHAR $9.67
- Analyst Decision
- GRAL Hold
- PHAR Strong Buy
- Analyst Count
- GRAL 2
- PHAR 3
- Target Price
- GRAL $16.00
- PHAR $27.00
- AVG Volume (30 Days)
- GRAL 967.4K
- PHAR 5.8K
- Earning Date
- GRAL 02-15-2025
- PHAR 03-13-2025
- Dividend Yield
- GRAL N/A
- PHAR N/A
- EPS Growth
- GRAL N/A
- PHAR N/A
- EPS
- GRAL N/A
- PHAR N/A
- Revenue
- GRAL $117,669,000.00
- PHAR $285,745,000.00
- Revenue This Year
- GRAL $32.48
- PHAR $20.08
- Revenue Next Year
- GRAL $14.72
- PHAR $9.22
- P/E Ratio
- GRAL N/A
- PHAR N/A
- Revenue Growth
- GRAL 111.83
- PHAR 30.64
- 52 Week Low
- GRAL $12.33
- PHAR $6.65
- 52 Week High
- GRAL $24.92
- PHAR $13.20
- Technical
- Relative Strength Index (RSI)
- GRAL N/A
- PHAR 52.85
- Support Level
- GRAL N/A
- PHAR $9.37
- Resistance Level
- GRAL N/A
- PHAR $10.15
- Average True Range (ATR)
- GRAL 0.00
- PHAR 0.48
- MACD
- GRAL 0.00
- PHAR -0.11
- Stochastic Oscillator
- GRAL 0.00
- PHAR 27.46
About GRAL GRAIL INC
GRAIL Inc is a healthcare company focused on developing technologies for early cancer detection. The company has developed a multi-cancer early detection blood test that has the ability to detect all types of cancer, across all stages.
About PHAR Pharming Group N.V.
Pharming Group is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. It is commercializing and developing an innovative portfolio of protein replacement therapies and precision medicines to serve the unserved rare disease patients. Its product includes Ruconest. The revenue is generated from the United States.